Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (September 2021)
29 slides from Matinas Biopharma's investor presentation, Sep 13, 2021
Slide 1: Matinas BioPharma Corporate Presentation September 2021
MATINAS BIOPHARMA XN Corporate Presentation \ September 2021
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other stat
Slide 3: Matinas is a True Platform Drug Delivery Company
Matinas is a True Platform Drug Delivery Compa’ — Lipid Nanocrystals (LNCs) FLEXIBLE ADMINISTRATION = Oral = Intravenous = Intramuscular = Inhalation PHYSIOLOGICALLY TARGETS ACTIVATED CELLS Comprised of phosphatidylserine (PS) and calcium (critical components of natural cellular fusion) Targets “act
Slide 4: LNC Program Highlights
LNC Program Highlights Vv © > y > > Vv Yu MAT2203 (oral amphotericin B) Lead LNC program in Phase 2 for treatment of Cryptococcal Meningitis (CM), a deadly invasive fungal infection ACHIEVED all primary and key secondary endpoints through Cohort 2 of EnACT Unanimous DSMB approval to proceed to Cohor
Slide 5: Lipid Nanocrystal (LNC) Platform
Lipid Nanocrystal (LNC) Platform Targeted, Well-Tolerated Intracellular Delivery e) MATINAS BIOPHARMA
Slide 6: The Current Landscape of Intracellular Drug Delivery
The Current Landscape of Intracellular Drug Delivery Contents to be delivered Small molecules: Gene therapy: © Antibiotic Antifungal Antiviral Anti-tumor Anti-inflammatory Oligonucleotides DNA mRNA siRNA CRISPR/Cas-9 Targets Therapeutic areas = Infected cells = Macrophages = Infectious disease » Inj
Slide 7: LNCs Fuse Together with Phosphatidylserine (PS) and Calcium and Then Fuse Directly with Cell Membranes
LNCs Fuse Together with Phosphatidylserine (PS) and Calcium and Then Fuse Directly with Cell Membranes Fusion of Cell Membranes LNCs are made by calcium-induced fusion of PS liposomes (endosomes, exosomes, vesicles, viruses) into lipid bilayer sheets and exposing them to Ca** Membrane contact Outer
Slide 8: LNCs Work Because of PS — A Key Component of LNCs AND Cell Membranes
LNCs Work Because of PS — A Key Component of LNCs AND Cell Membranes Cell Membrane Phosphatidylserine Normally, PS is confined to the inner layer [ Cytosol ] Inner layer (cytosolic) ait. FRRAR PPR RR PR With “activation” PS moves from the inner layer to the outer layer Ps Outer layer Causeceouseses
Slide 9: Role of PS and PS Receptors in the Uptake of LNCs into Cells
Role of PS and PS Receptors in the Uptake of LNCs into Cells Phagocytosis Initiated by binding of PS to PS receptors < PMA _ Macrophage Macrophages readily engulf LNCs and their cargo into vesicles (endosomes). Fusion Initiated by expression of PS on the surface of cells Intracellular delivery via p
Slide 10: LNCs Are Differentiated from Liposomes, LNPs and Viral Vectors
10 LNCs Are Differentiated from Liposomes, LNPs and Viral Vectors Liposome AAV (Viral Vecto! Aqueous interior surrounded by bilayer + lonizable lipid complexing with 26 nM Capsid housing <5 kb + Natural components + Non-aqueous bilayer Limited shelf life + Very limited shelf stability + Cold-chain r
Slide 11: MAT2203 Oral Amphotericin B
MAT2203 Oral Amphotericin B MATINAS BIOPHARMA
Slide 12: Invasive Fungal Infections Represent an Urgent Growing Global Need
Invasive Fungal Infections Represent an Urgent Growing Global Need Global Invasive fungal infection market value projected in 2025 ~$8B Potential for significant Amphotericin B market expansion Global Amphotericin B sales in 2018 Invasive fungal infections are an urgent and largely overlooked global
Slide 13: MAT2203: A Novel Approach with a Proven Therapeutic Agent
MAT2203: A Novel Approach with a Proven Therapeutic Agent MAT2203 IMPROVED PROFILE POTENTIAL CLINICAL IMPACT 13 Oral amphotericin B formulation utilizing LNCs Proprietary formulation with robust intellectual property protection Potential to expand beyond treatment of CM to treatment of other invasiv
Slide 14: EnACT Study Design
EnACT Study Design Inductio n (2 weeks) ¥ Cohort1 MWA (n=10) 5 days 10 ¢ Y Cohort 2 #AWE MV (n=40) 2 days 1 Cohort 3 MAT2: (n=10) 5 Cohort 4 M (n=40) 2 IV AMB 10 days (overlap 1 day) Adjunctive Rx 5FC . ee —e,... Early Consolidation (4 weeks) (all cohorts) 14 : - *IV AMB = intravenous amphotericin B
Slide 15: Key Elements of EnACT and Potential Indications
Key Elements of EnACT and Potential Indications = Sequential cohort, gradually extending use of oral MAT2203, to assess safety and efficacy = Strategic design, providing data to support up to three potential indications = Rigorous safety monitoring; DSMB review after each cohort Step-down induction
Slide 16: EnACT — Baseline and Demography Summary
EnACT — Baseline and Demography Summary = 71 total patients were randomized in Cohorts 1 and 2 = Cohort 1 (MAT2203): 10 patients = Cohort 2 (MAT2203): 40 patients = SOC (combined): 21 patients = Demographic and baseline characteristics were comparable across the treatment groups = First episode of C
Slide 17: EnACT — Efficacy Endpoints and Analyses
EnACT — Efficacy Endpoints and Analyses = Primary Endpoint: EFA (log,, CFU/mL/day) at Day 14 = Rate of CSF fungal clearance (log reduction) = Quantitative measure of antifungal activity of an induction treatment for CM = Early surrogate marker that predicts survival = Primary Endpoint Objective: Dem
Slide 18: EnACT — Efficacy Results for Cohort 2
18 EnACT — Efficacy Results for Cohort 2 Primary endpoint : EFA for MAT2203 treated patients > 0. Key primary and secondary endpoints: 1) EFA: 2) Patients achieving sterile culture while on MAT2203 3) Patients with relapse or breakthrough infections 4) Patient survival” 5) Patients with MAT2203-rela
Slide 19: EnACT Cohort 2 — Summary of Overall Safety and Efficacy
EnACT Cohort 2 —Summary of Overall Safety and Efficacy Safety Efficacy = MAT2203 was safe and well-tolerated over 6 weeks = EFA for MAT2203 was 0.38 (95% CI 0.30 to 0.46), meeting the of treatment primary endpoint for the study * No renal toxicity or electrolyte abnormalities = Also met major clinic
Slide 20: EnACT Cohort Results Provide Important Validation of LNC Platform Capabilities
EnACT Cohort 2 Results Provide Important Validation of LNC Platform Capabilities * The EnACT Cohort 2 results are an important demonstration of how Matinas’ LNC platform can provide meaningful clinical impact in a deadly disease * They validate the use of the platform to overcome significant deliver
Slide 21: MAT2501 Oral Amikacin
MAT2501 Oral Amikacin MATINAS BIOPHARMA
Slide 22: MAT2501: A Better Amikacin
22 MAT2501: A Better Amikacin MAT2501 IMPROVED * PROFILE . SIGNIFICANT . UNMET NEED . Oral, LNC formulation of the broad-spectrum antibiotic Amikacin Initial indication in treatment of non-tuberculous mycobacterial (NTM) infections QIDP and Orphan Designations potentially provide 12+ years of exclus
Slide 23: NTM Program Overview
1: NTM Program Overview Non-Tuberculous Mycobacterial Disease NTM organisms, widely present in the environment, are a frequent cause of challenging pulmonary infections, especially in patients with pre-existing inflammatory lung diseases such as cystic fibrosis Approximately 40-60% of patients have
Slide 24: Potential Opportunities for Further Exploration
Potential Opportunities for Further Exploration The LNC Platform has already demonstrated significant potential to move well beyond the current capabilities of LNPs and viral vectors in the following areas: >» Oligonucleotides - Efficient, non-toxic delivery > mRNA - Enhanced stability (even at room
Slide 25: Driving Opportunities for Value-Added Partnerships Built around the LNC Platform
Driving Opportunities for Value-Added Partnerships Built around the LNC Platform Genentech A Member of the Roche Group J GILEAD aa® CYSTIC FIBROSIS FOUNDATION’ 25 Working with multiple strategic and research partners to expand potential successful applications of our LNC technology. In 2019, we ente
Slide 26: Expanding LNC Intellectual Property Portfolio
Expanding LNC Intellectual Property Portfolio 24 ISSUED PATENTS EXTEND TO AT LEAST 2033 16 Patents Issued Within Last 4 Years 3 8 Regulatory PENDING PATENT Exclusivities APPLICATIONS ACROSS PLATFORM Additional IP to be developed as MAT2203 and MAT2501 both clinical development plan have QIDP and Orp
Slide 27: LYPDISO™ - Representing the Next Generation in RX Omega-3
LYPDISO™ - Representing the Next Generation in RX Omega-3 27 Product Profile Proprietary formulation of omega-3 fatty acids comprising primarily EPA and DPA ina free fatty acid molecular form to optimize bioavailability Specifically designed to optimize treatment of dyslipidemia and severe hypertrig
Slide 28: Executive Officers and Board of Directors
Executive Officers and Board of Directors EXECUTIVE OFFICERS Jerome D. Jabbour Co-Founder, Chief Executive Officer James J. Ferguson Ill, M.D., FACC, FAHA Chief Medical Officer Theresa Matkovits, Ph.D. Chief Development Officer Keith A. Kucinski, CPA, MBA Chief Financial Officer Raphael J. Mannino,
Slide 29: Matinas BioPharma
MATINAS BIOPHARMA Corporate Presentation ' September 2021
Matinas BioPharma Holdings — Investor Presentation (September 2021) on 6ix